Subscribe to RSS
DOI: 10.1055/s-0037-1614945
Standardization of the APC Resistance Test. Effects of Normalization of Results by Means of Pooled Normal Plasma
Publication History
Received
14 August 1997
Accepted after revision
29 October 1997
Publication Date:
07 December 2017 (online)
Summary
Results for APC resistance tests are expressed as the ratio of the clotting time with and without APC (APC ratio). Normalization by dividing the patient’s APC ratio by that of the pooled normal plasma (PNP) (n-APC ratio) was proposed to minimize between-lot reagent variability. To evaluate the merits of different expressions of the results, sets of 80 coded frozen plasmas from carriers (n = 30), non-carriers (n = 30) of the FV:Q506 mutation and 10 copies each of two control plasmas were sent to 7 expert laboratories which were asked to assess APC resistance by their methods. Results were expressed as APC ratio and nAPC ratio by the local PNP and 2 common PNP (A and B). These contained plasmas from the same (n = 20) non-carriers. In PNP A, plasma from one non-carrier was replaced with that from one heterozygous carrier. The merits of different expression of results were judged by (i) within-laboratory reproducibility; (ii) discrimination of carriers from non-carriers; (iii) between-method comparability of results. The influence of FV:Q506 plasma in the preparation of PNP was also assessed. Reproducibility, generally good even with results expressed as APC ratio (median CV 4.6% and 3.0% for normal and abnormal control), was not changed by normalization. Discrimination did not change whatever the method of result expression. Between-method comparability of results was scarcely affected by normalization with the local PNP, whereas it was considerably improved after normalization with the common PNP, but only for the non-carriers. APC ratios for PNP A by all methods were significantly lower than those for PNP B. Thus, the presence of mutant FV in a proportion as low as 2.5% may reduce the APC ratio of the PNP.
-
References
- 1 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a pre viously unrecognized mechanism characterized by a poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
- 2 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated to activated protein C. Nature 1994; 369: 64-7.
- 3 de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-6.
- 4 Tripodi A, Negri B, Bertina RM, Mannucci PM. Screening for the FV:Q506 mutation. Evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis. Thromb Haemost 1997; 77: 436-9.
- 5 Dahlbäck B. Resistance to activated protein C, the Arg 506 Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assay, Pros and Cons. Thromb Haemost 1995; 73: 739-42.
- 6 Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.